Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Pirfenidone in Oral Submucous Fibrosis
NCT06871904Phase 2Completed
- Sponsor
- Ziauddin University
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) and pirfenidone in Oral submucous fibrosis (OSF) (3 arms), sponsored by Ziauddin University. Primary endpoints: Change in Exosome Secretion and Characterization in OSF Cell Lines at 72 hours, Changes in Fibrosis-Related Gene Expression in OSF Cell Lines at 48 hours and 2 more. Started Apr 2025; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)pirfenidone
03
Conditions
Oral submucous fibrosis (OSF)
Beyond the preview
Go deeper on NCT06871904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871904.